Skip to main content
OpenTrials
Completed

NCT Number: NCT03443349

"Vibwife One" a New Medical Device to Support Delivering Women in Their Mobilization

"Vibwife One" was developed to support the mobilization of the delivering women during the labor process. It consists of a mattress that fits on existing delivery beds. Different movements, adjustable in pace and intensity can be chosen to mobilize women in labor.

Although existing evidence is rare, some literature and historical reports have shown a positive impact of active mobilization during labor.

At time of rising epidural anesthesia rate, "Vibwife One" could be an interesting way to active mobilize those women to support the physiological birth process.

So far, the device has not yet been applied in delivering women. The investigators carry out a first safety study to assess the safety, to evaluate the comfort and the practicability for delivering women and medical staff of this new medical device.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Medical Device

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Basel

Basel, Canton of Basel-City, 4031, Switzerland

About this study

The medical device will be used according to its market authorization. Because it will be used for the first time in pregnant women, the following three step application procedure has been determined:

  • First five pregnant women use the device for 10 minutes. Each of them in a position and module proposed by the midwife with the agreement of the woman.
  • Next 10 pregnant women use the device for 20 minutes. Again, position and module according to the decision of the midwife with the agreement of the woman.
  • All the remaining pregnant women (35) use the device for 30 minutes. Position and module according to the decision of the midwife with the agreement of the woman.

During the intervention period, position and module might be changed once if required.

After the inclusion of all the 50 participants, each position and module has to be tested.

There will be a safety review board consisting of one physician, one midwife and a clinical expert midwife meeting after each group of pregnant women having used the device, evaluating the safety criteria according to predefined Adverse Device Effects and Adverse Events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent documented by signature
  • German or English speaking
  • Singleton healthy pregnancy
  • Cephalic presentation
  • ≥37th weeks of gestation
  • 4cm - 9cm of dilatation
  • Regular contractions
  • Physiological cardiotocograph (CTG) 30 min pre-intervention
  • Physiological blood pressure (111/66 - 139/89)

Exclusion criteria

  • Multiple pregnancies
  • Breech position
  • Small for gestational age (<10. Percentile)
  • Fetal congenital abnormalities
  • Placenta praevia
  • Fetal distress
  • Heavy vaginal bleeding during birth
  • Maternal weight ≥ 135 kg
  • Preeclampsia or HELLP
  • Diabetes I and II / Gestational diabetes insulin dependent
  • Spinal and back disorder (herniated disk / scoliosis)
  • Hypertension (≥140/90 mmHg)
  • Hypotension (Basic blood pressure in the third trimester -20%, if not available: ≤ 110/65 mmHg)
  • No signed informed consent

Treatment and study plan

Vibwife One

Device

Vibwife One is a powered rotation bed intended to be used to assist in active mobilization of delivering women. "Vibwife One" imitates manual mobilization and position techniques. It is integrated in the mattress and fixed to the pelvis area of the birthing bed. "Vibwife One" can be used, when manual mobilization and position techniques are deemed appropriate.

The device with all its functions is controlled over a remote control.

Primary outcomes

  1. Safety measured by number of Adverse Events and Adverse Device Effects

    Time frame: During intervention and until 30min. after end of intervention

    The Primary outcome is safety of the pregnant woman and the child using "Vibwife One" in the first stage of Labor. It will be evaluated according to predefined Adverse Events and Adverse Device Effects.

Secondary outcomes

  1. Pain intensity

    Time frame: VAS before, during and after end of the intervention, intervention lasting up to 30 min.

    Pain intensity is measured by a discrete Visual Analogue Scale (VAS) from 0-10, 0 indicating no pain until 10 indicating greatest pain

  2. Preferences measured by questionnaire

    Time frame: within 30 minutes after end of the intervention, intervention lasting up to 30 min.

    Women's preferences regarding the medical device will be measured by a questionnaire with a 4-issue Likert scale; Likert scaling is a bipolar scaling method, measuring either positive or negative response to a statement. The responses in this study might be 1.Strongly disagree, 2.Disagree, 3.Agree 4. Strongly agree, answers ranging from 1 point (strongly disagree) to 4 points (strongly agree). Low amount of points represent a better outcome.

  3. Practicability measured by questionnaire

    Time frame: from first birth in the study until last birth in the study (start of study until study completion an average of 1 year)

    Practicability of the medical device and views of the midwives and physicians will be assessed by a questionnaire with a 4-issue Likert scale; Likert scaling is a bipolar scaling method, measuring either positive or negative response to a statement. The responses in this study might be 1.Strongly disagree, 2.Disagree, 3.Agree 4. Strongly agree, answers ranging from 1 point (strongly disagree) to 4 points (strongly agree). Low amount of points represent a better outcome.

Other outcomes

  1. Duration of first stage of labor measured by hours

    Time frame: assessed during birth

    The first stage is defined from 4cm till full dilatation (10cm) of the cervix

  2. Duration of second stage of labor measured by hours

    Time frame: assessed during birth

    The second stage is defined as part of labor from the full dilatation of the Cervix until birth

  3. Delivery Outcome measured by frequency of route of delivery

    Time frame: from first birth in the study until last birth in the study (start of study until study completion an average of 1 year)

    Frequencies and means of characteristics of delivery (spontaneous versus vaginal instrumental versus caesarian section)

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Collaborators

  • Clinical Trial Unit, University Hospital Basel, Switzerland

Registry information

Official study title

A Single - Centre Safety Study About the Safety, Practicability and Acceptance of "Vibwife One", a New Medical Device to Support Delivering Women in Their Mobilization

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Feb 23, 2018
Registry last updated
Nov 14, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.